Home  |  Contact

Cellosaurus 8505C (CVCL_1054)

Cell line name 8505C
Synonyms 8505c
Accession CVCL_1054
Resource Identification Initiative To cite this cell line use: 8505C (RRID:CVCL_1054)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: TCGA-110-CL cell line panel.
Population: Japanese.
Doubling time: 36 hours (PubMed=21566963); ~30-40 hours (DSMZ=ACC-219); ~1.5 days (Note=Lot 11252003) (JCRB=JCRB0826).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Misspelling: 8509C; Cosmic=1132598.
Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 7773; NF2; Simple; p.Glu129Ter (c.385G>T); Zygosity=Homozygous (PubMed=30737244; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gly (c.742C>G); ClinVar=VCV000376652; Zygosity=Hemizygous (PubMed=1516062; PubMed=14522906; PubMed=21566963; PubMed=23162534; PubMed=30737244; Cosmic-CLP; DepMap).
HLA typing Source: PubMed=26589293
Class I
HLA-AA*02:01,26:01
HLA-BB*39:01,51:01
HLA-CC*07:02,15:02
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.58
Native American0
East Asian, North84.79
East Asian, South11.83
South Asian0
European, North0
European, South2.8
Disease Thyroid gland anaplastic carcinoma (NCIt: C3878)
Anaplastic thyroid carcinoma (ORDO: Orphanet_142)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 78Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=18713817; PubMed=21868764; PubMed=25877200; PubMed=30737244; RCB; TKG

Markers:
AmelogeninX
CSF1PO12,13
D2S133817,24
D3S135816,17
D5S81810,11
D7S82010
D8S117910,13
D13S31713
D16S53912
D18S5116
D19S43313,14
D21S1128,32.2
FGA23
Penta D9,10
Penta E12,15
TH016 (PubMed=25877200)
6,9 (Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=21868764; PubMed=30737244; RCB; TKG)
TPOX10,11 (Cosmic-CLP; DSMZ; PubMed=30737244; RCB; TKG)
11 (ECACC; JCRB; PubMed=21868764; PubMed=25877200)
vWA17,19

Run an STR similarity search on this cell line
Publications

PubMed=1516062
Yoshimoto K., Iwahana H., Fukuda A., Sano T., Saito S., Itakura M.
Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.
Cancer Res. 52:5061-5064(1992)

PubMed=21566963; DOI=10.3892/ijo.4.3.583
Ito T., Seyama T., Hayashi Y., Hayashi T., Dohi K., Mizuno T., Iwamoto K.S., Tsuyama N., Nakamura N., Akiyama M.
Establishment of 2 human thyroid-carcinoma cell-lines (8305C, 8505C) bearing p53 gene-mutations.
Int. J. Oncol. 4:583-586(1994)

PubMed=9247707; DOI=10.1080/15216549700202901
Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.
Expression of bone morphogenetic proteins of human neoplastic epithelial cells.
Biochem. Mol. Biol. Int. 42:497-505(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=14522906
Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 63:5829-5837(2003)

PubMed=15613457; DOI=10.1677/erc.1.00818
Onda M., Emi M., Yoshida A., Miyamoto S., Akaishi J., Asaka S., Mizutani K., Shimizu K., Nagahama M., Ito K., Tanaka T., Tsunoda T.
Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes.
Endocr. Relat. Cancer 11:843-854(2004)

PubMed=16924234; DOI=10.1038/sj.onc.1209899
Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.
A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.
Oncogene 26:1178-1187(2007)

PubMed=17725429; DOI=10.1089/thy.2007.0097
Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M.
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Thyroid 17:707-715(2007)

PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026
van Staveren W.C.G., Weiss-Solis D.Y., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C.
Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype.
Cancer Res. 67:8113-8120(2007)

PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=19087340; DOI=10.1186/1471-2407-8-371
Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.
Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.
BMC Cancer 8:371.1-371.11(2008)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23162534; DOI=10.3389/fendo.2012.00133
Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A., van Staveren W.C.G., Maenhaut C.
Thyroid cancer cell lines: an overview.
Front. Endocrinol. 3:133.1-133.9(2012)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574.1-3574.11(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) AddexBio; C0025002/19
BCRJ; 0398
DSMZ; ACC-219
ECACC; 94090184
JCRB; JCRB0826
RCB; RCB2103
TKG; TKG 0439
Cell line databases/resources CLO; CLO_0001513
CLO; CLO_0050951
CLDB; cl135
CLDB; cl136
cancercelllines; CVCL_1054
Cell_Model_Passport; SIDM00996
CGH-DB; 54-1
Cosmic-CLP; 924102
DepMap; ACH-001307
DSMZCellDive; ACC-219
LINCS_LDP; LCL-1686
Anatomy/cell type resources BTO; BTO:0005550
Biological sample resources BioSample; SAMN01821611
BioSample; SAMN03470935
BioSample; SAMN03472518
BioSample; SAMN03473379
BioSample; SAMN10988556
Chemistry resources ChEMBL-Cells; CHEMBL3308353
ChEMBL-Targets; CHEMBL1075387
GDSC; 924102
PharmacoDB; 8505C_31_2019
PubChem_Cell_line; CVCL_1054
Encyclopedic resources Wikidata; Q54605341
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM886847
GEO; GSM887911
GEO; GSM1669574
Polymorphism and mutation databases Cosmic; 889489
Cosmic; 891256
Cosmic; 922365
Cosmic; 924102
Cosmic; 1084283
Cosmic; 1132598
Cosmic; 1152114
Cosmic; 1162837
Cosmic; 1239959
Cosmic; 2036694
Cosmic; 2054105
Cosmic; 2613248
IARC_TP53; 1305
LiGeA; CCLE_065
Progenetix; CVCL_1054
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number45